Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
As equity markets show signs of fatigue after a prolonged bull run, defensive sectors like utilities are gaining attention. The Vanguard Utilities ETF (VPU), with its low cost and stable dividend yield, presents a compelling option for investors seeking to buffer their portfolios against potential volatility.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Six Italian police and coastguard members face trial for alleged negligence in the Cutro shipwreck that killed at least 94 migrants, a case testing Italy's hardline migration policies.
Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.
Truist Securities has lowered its price target on Landstar System (LSTR) from $150 to $145, maintaining a Hold rating following the logistics provider's fourth-quarter earnings miss. Analysts cite one-time insurance costs as a drag, while noting core fundamentals have yet to show a decisive turnaround.
Analysts at TD Cowen have significantly raised their price target for GE Vernova (GEV) to $780, maintaining a Buy rating after the company's robust Q4 performance exceeded expectations on orders and pricing power.
President Donald Trump announces his intent to nominate former Fed Governor Kevin Warsh as the next Federal Reserve Chair, seeking a leader aligned with his economic vision amid debates over interest rates and inflation.
As severe flooding displaces hundreds of thousands in Mozambique, the UN raises alarms over dangerously overcrowded temporary shelters and a critical funding shortfall, warning of heightened risks for vulnerable populations.
Investment firm Giverny Capital has sold its entire position in used-car retailer CarMax, a holding of several years, as detailed in its Q4 2025 investor letter. The move highlights a strategic pivot away from traditional retail plays towards perceived higher-growth opportunities in technology, even as the firm's portfolio underperformed major indices last quarter.
Despite a recent 13% quarterly dip, Digital Turbine (NASDAQ: APPS) has delivered a staggering 116% return to investors over the past twelve months. This surge comes even as the mobile software company remains unprofitable, raising questions about the drivers behind its market optimism and its long-term trajectory.
Equifax is expanding beyond traditional credit reporting with a new suite of AI-powered fraud detection and income verification tools. While this strategic push aims to embed the company deeper into the lending ecosystem, analysts remain divided on whether it's enough to support its current valuation amid high debt and execution risks.
Eaton Corporation's shares have surged approximately 10% over the past month, reigniting the debate on its true valuation. While some models point to significant upside, a discounted cash flow analysis suggests caution, highlighting the divergent narratives investors must navigate.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
Global spirits giant Diageo is exploring a sale of its high-profile Indian Premier League cricket franchise, Royal Challengers Bengaluru, as part of a strategic review of its Indian assets. Major private equity firms are circling, signaling strong interest in one of sports' most valuable properties.
